 |
|
|
| |
Coadministration of HCV Protease Inhibitor Grazoprevir With HCV NS5A Inhibitor Elbasvir Has No Effect On Pravastatin But Increases Rosuvastatin Exposure In Healthy Subjects
|
| |
| |
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. Washington DC, May 26-28, 2015
Clinical Pharm of HIV & Hepatitis Drug-Drug Interactions with
Grazoprevir/Elbasvir: Practical Considerations for the Care of HIV/HCV
Co-Infected Patients - (06/03/15)
L. Caro1, W. Marshall2, H. Feng1, Z. Guo3, D. Wolford4, D. Stypinski5, M. Dupuis5, J. Bredja6, C. Mitchell7, J.M. Allison8, M. Iwamoto9, J. Butterton2, W.W. Yeh2
1Merck & Co. Inc., Quantitative Pharmacokinetics and Pharmacometrics, West Point, USA; 2Merck & Co. Inc., Clinical Pharmacology Experimental Therapeutics, Boston,
USA; 3Merck & Co. Inc., Biostatistics, Upper Gwenydd, USA; 4Merck & Co. Inc., Early Stage Operations, Upper Gwenydd, USA; 5Celerion, Pharmacokinetics, Tempe, USA; 6Celerion, Statistics, Tempe, USA; 7Celerion, Medical Writing, Tempe, USA; 8Celerion, Clinical, Tempe, USA; 9Merck & Co. Inc., Clinical Pharmacology Experimental Therapeutics, Rahway, USA
|
| |
|
|
|
|
|
